Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXS NASDAQ:NBTX NASDAQ:SLDB NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXSAstria Therapeutics$7.27-1.4%$6.71$3.56▼$12.92$410.28M0.42357,040 shs389,272 shsNBTXNanobiotix$9.74+4.5%$7.52$2.76▼$10.59$466.97M0.4711,728 shs16,841 shsSLDBSolid Biosciences$5.41-1.5%$5.96$2.41▼$8.10$421.28M2.541.80 million shs715,006 shsTCRXTScan Therapeutics$1.72+1.8%$1.80$1.02▼$6.23$97.61M1441,023 shs190,695 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXSAstria Therapeutics-0.81%-0.81%+7.59%+29.30%-33.84%NBTXNanobiotix-3.92%+7.00%+17.83%+102.39%+88.28%SLDBSolid Biosciences+1.86%+7.02%-10.15%+19.09%-30.77%TCRXTScan Therapeutics-3.98%-10.11%-6.11%+9.74%-70.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXSAstria Therapeutics$7.27-1.4%$6.71$3.56▼$12.92$410.28M0.42357,040 shs389,272 shsNBTXNanobiotix$9.74+4.5%$7.52$2.76▼$10.59$466.97M0.4711,728 shs16,841 shsSLDBSolid Biosciences$5.41-1.5%$5.96$2.41▼$8.10$421.28M2.541.80 million shs715,006 shsTCRXTScan Therapeutics$1.72+1.8%$1.80$1.02▼$6.23$97.61M1441,023 shs190,695 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXSAstria Therapeutics-0.81%-0.81%+7.59%+29.30%-33.84%NBTXNanobiotix-3.92%+7.00%+17.83%+102.39%+88.28%SLDBSolid Biosciences+1.86%+7.02%-10.15%+19.09%-30.77%TCRXTScan Therapeutics-3.98%-10.11%-6.11%+9.74%-70.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXSAstria Therapeutics 3.14Buy$29.00298.90% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00-17.86% DownsideSLDBSolid Biosciences 3.09Buy$15.00177.26% UpsideTCRXTScan Therapeutics 3.00Buy$7.80353.49% UpsideCurrent Analyst Ratings BreakdownLatest TCRX, SLDB, ATXS, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.008/13/2025ATXSAstria TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/13/2025ATXSAstria TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $26.008/13/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $14.008/12/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.007/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXSAstria TherapeuticsN/AN/AN/AN/A$3.97 per shareN/ANBTXNanobiotix-$11.61M-40.22N/AN/A($1.51) per share-6.45SLDBSolid Biosciences$8.09M52.07N/AN/A$3.43 per share1.58TCRXTScan Therapeutics$2.82M34.61N/AN/A$4.26 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXSAstria Therapeutics-$94.26M-$2.01N/AN/AN/AN/A-56.39%-36.08%11/12/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)TCRXTScan Therapeutics-$127.50M-$1.09N/AN/AN/A-1,964.88%-63.33%-40.19%11/11/2025 (Estimated)Latest TCRX, SLDB, ATXS, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ATXSAstria Therapeutics-$0.61-$0.57+$0.04-$0.57$16.00 millionN/A8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/12/2025Q2 2025TCRXTScan Therapeutics-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXSAstria TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXSAstria TherapeuticsN/A14.8914.89NBTXNanobiotixN/A1.041.04SLDBSolid BiosciencesN/A9.349.34TCRXTScan Therapeutics0.187.067.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXSAstria Therapeutics98.98%NBTXNanobiotix38.81%SLDBSolid Biosciences81.46%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipATXSAstria Therapeutics4.50%NBTXNanobiotix3.45%SLDBSolid Biosciences13.63%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXSAstria Therapeutics3056.44 million53.90 millionOptionableNBTXNanobiotix10047.94 million46.29 millionNot OptionableSLDBSolid Biosciences10077.87 million67.26 millionOptionableTCRXTScan Therapeutics10056.75 million54.28 millionNot OptionableTCRX, SLDB, ATXS, and NBTX HeadlinesRecent News About These CompaniesEcoR1 Capital LLC Sells 4,337,167 Shares of TScan Therapeutics, Inc. $TCRXSeptember 6, 2025 | marketbeat.comTScan Therapeutics, Inc. $TCRX Shares Bought by Checkpoint Capital L.P.September 6, 2025 | marketbeat.comBVF Inc. IL Purchases 1,900,000 Shares of TScan Therapeutics, Inc. $TCRXSeptember 5, 2025 | marketbeat.comTScan Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by BrokeragesAugust 30, 2025 | marketbeat.comTocqueville Asset Management L.P. Sells 233,870 Shares of TScan Therapeutics, Inc. $TCRXAugust 21, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for TCRX FY2025 Earnings?August 19, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TCRX FY2025 EarningsAugust 17, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for TCRX Q3 Earnings?August 17, 2025 | marketbeat.comWedbush Cuts Earnings Estimates for TScan TherapeuticsAugust 17, 2025 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash WiselyAugust 15, 2025 | finance.yahoo.comTScan Therapeutics Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comTScan Therapeutics reports Q2 EPS (28c), consensus (32c)August 12, 2025 | msn.comTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comTScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comTScan Therapeutics Elects New Directors at Annual MeetingJuly 27, 2025 | theglobeandmail.comOne TScan Therapeutics Insider Raised Stake By 18% In Previous YearJuly 19, 2025 | finance.yahoo.comTscan Therapeutics Inc News (TCRX) - Investing.comJuly 9, 2025 | investing.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comWhat Analysts Are Saying About TScan Therapeutics StockMay 9, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRX, SLDB, ATXS, and NBTX Company DescriptionsAstria Therapeutics NASDAQ:ATXS$7.27 -0.10 (-1.36%) Closing price 04:00 PM EasternExtended Trading$7.26 -0.01 (-0.14%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Nanobiotix NASDAQ:NBTX$9.74 +0.42 (+4.51%) Closing price 03:50 PM EasternExtended Trading$9.76 +0.02 (+0.20%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Solid Biosciences NASDAQ:SLDB$5.41 -0.08 (-1.46%) Closing price 04:00 PM EasternExtended Trading$5.48 +0.08 (+1.39%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.TScan Therapeutics NASDAQ:TCRX$1.72 +0.03 (+1.78%) Closing price 04:00 PM EasternExtended Trading$1.73 +0.01 (+0.58%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
